Search results
Results from the WOW.Com Content Network
COVID-19 vaccines gave Moderna, Pfizer and Johnson & Johnson a boost — but are their stocks still good buys in 2021? Here's what to consider before investing.
If you want to explore similar stocks, you can also take a look at 5 Best Vaccine Stocks To Buy Now. One of the most defensive areas of the market is healthcare, and in 2022 when the markets are ...
As people acclimatize to the new normal, it’s time to look at some vaccine stocks to sell. Instead of relying primarily on vaccines and antiviral drugs, the government let people manage infections.
The early lead in the vaccine race went to Moderna -- shares skyrocketed in late February when the company announced it would be working on a vaccine alongside the National Institute of Allergy ...
In July 2018, it filed an application to list on the Hong Kong Stock Exchange. [1] It debuted on 28 March 2019 with an increase of 59%, the highest first day trading gain in Hong Kong since 2017. [2] In August 2020, it completed a secondary offering on Shanghai Stock Exchange's STAR market where it raised 5.2 billion yuan (US$750 million). [3]
In March 2020, CEPI invested US$4.4 million in two more projects with Swedish vaccine laboratory Novavax, and with Oxford University, bringing its total investment in SARS-CoV-2 vaccine work to US$23.7 million, and announcing that it would invest up to US$100 million in further COVID-19 projects.
Facing such uncertainty, Pfizer cut its full-year adjusted earnings guidance to a range of $1.45 to $1.65 per share — a far cry from the prior estimate of $3.25 to $3.45 per share — causing ...
24.2 37 After Boston Scientific increased their offer to $25 billion, Johnson & Johnson further increased their offer to $24.2 billion. 27 2006 Johnson & Johnson: Guidant: 23.2 35 After the re-negotiated a lower price of $21.5 billion was trumped by Boston Scientifics offer of $24.6 billion, Johnson & Johnson raised their offer to $23.2 billion. 28